5.3.1.5. Other HIV combination preparations
Combination preparations that consist of drugs from the different classes of HIV medicines are included in this sub-section.
Restrictions:
Restricted to use by HIV specialists for the treatment of adults infected with HIV-1 without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.
Restrictions:
Restricted to use by HIV specialists for treatment of adults infected with HIV-1 who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor.
Restrictions:
Restricted as outlined in the Prescribing Notes section below.
Prescribing Notes:
Treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus-1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir is restricted to use by HIV specialist only.
Restrictions:
Restricted to use by HIV specialists.
Prescribing Notes:
Please note: Only this combination preparation containing cobicistat is included in the Formulary. Cobicistat tablets as a separate preparation (Tybost®) are not recommended for use by the Scottish Medicines Consortium and are non-Formulary.
Restrictions:
The use for the treatment of HIV-1 infection in treatment naive adults, or treatment experienced adults without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load ≤100,000 HIV-1 RNA copies/mL, is restricted to HIV specialists only.
Restrictions:
Use in the treatment of HIV infection is restricted to use by HIV specialists only.
Use for the pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk men who have sex with men, including adolescents (with body weight at least 35 kg) is restricted to specialist use for those patients who have renal or bone issues for whom other alternative PrEP options are not suitable.
Prescribing Notes:
Preferred preparation for PrEP in NHSGGC is generic Emtricitabine/tenofovir disoproxil.
Restrictions:
- The treatment of HIV infection is restricted to use by HIV specialists.
- Use in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk is restricted to specialist use only by consultants in sexual health and infectious disease consultants.
Prescribing Notes:
Preferred preparation for PrEP in NHSGGC.
Non-Formulary indications:
- Treatment of HIV-1 infected adolescents aged 12 to <18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first-line agents